Oct 2026
Deep clinical renal response in lupus nephritis treated with belimumab: a real-world cohort study.
OBJECTIVES Lupus nephritis (LN) often progresses despite therapy, and current complete renal response (CRR) definitions tolerate residual proteinuria deemed suboptimal in other glomerulopathies. Belimumab, the first biologic approved for active LN, may enable deeper remission, but its real-world effectiveness is unknow...
Marc Xipell, M. C. Garbarino, I. Rodríguez-Pintó et al.
· Rheumatology · 0 citations